LAS17 is a potent and selective tyrosine-directed irreversible inhibitor for glutathione S-Transferase Pi ( GSTP1 ). LAS17 inhibits GSTP1 activity with an IC 50 of 0.5 µM .
In Vitro
Glutathione S-Transferase Pi (GSTP1) mediates cellular defense against reactive electrophiles. LAS17 inhibits GSTP1 activity in vitro in a concentration-dependent manner. LAS17 (10 µM; Serum-free survival 48 h) treatment in 231MFP breast cancer cells recapitulates the serum-free cell survival impairments observed with genetic inactivation of GSTP1. GSTP1 knockdown in LAS17 (10 µM) treatment in 231MFP cells results in increased levels of phosphorylated AMPK and acetyl CoA carboxylase (ACC). LAS17 treatment in 231MFP cells also shows reduced levels of ATP, lactic acid, purine nucleotides, and diacylated phospholipids and alkylacyl ether lipids and increased levels of acyl carnitines (ACs), ceramides, lysophospholipids. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: 231MFP breast cancer cells Concentration: 10 µM Incubation Time: 48 hours Result: Recapitulated the serum-free cell survival impairments observed with genetic inactivation of GSTP1. Western Blot AnalysisCell Line: 231MFP cells Concentration: 10 µM Incubation Time: Result: LAS17-treated 231MFP cells show increased levels of phosphorylated AMPK and ACC.
In Vivo
Daily administration of LAS17 (20 mg/kg ip, once per day) significantly impairs 231MFP breast tumor xenograft growth in immune-deficient mice when treatment is initiated 2 days after subcutaneous injection of cells, and LAS17 even slows tumor growth when initiated 16 days after tumor implantation, with no observable toxicity and no weight-change. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Severe combined immunodeficiency (SCID) mice bearing 231MFP tumor xenograftDosage: 20 mg/kg (prepared in PBS:ethanol:PEG40 (18:1:1)) Administration: Daily administration i.p., once per day Result: Significantly impaired 231MFP breast tumor xenograft growth.
